Ed Arce
Stock Analyst at HC Wainwright & Co.
(3.74)
# 734
Out of 4,918 analysts
482
Total ratings
42.46%
Success rate
10.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Assumes: Buy | $30 | $15.63 | +91.94% | 21 | Jun 11, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $12 | $0.61 | +1,870.44% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $75 | $4.20 | +1,685.71% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $12.30 | +387.80% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $3.72 | +101.61% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $3.31 | +292.75% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $3.65 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $0.40 | +1,407.54% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $7.41 | +844.67% | 6 | Mar 31, 2025 | |
| DRRX DURECT | Reiterates: Neutral | n/a | $1.84 | - | 13 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $18.25 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $0.31 | +3,808.79% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.58 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $8.25 | +287.88% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $35 | $62.90 | -44.36% | 22 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $75 | $48.37 | +55.05% | 25 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $29 → $21 | $9.16 | +129.26% | 22 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $52.02 | +38.41% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $302.17 | +34.03% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $4.33 | +27.02% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $28.44 | +234.04% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $7.11 | +153.16% | 11 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $3.87 | +235.92% | 18 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $3.27 | +52.91% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $21.28 | +125.56% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $5.47 | +37.11% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.73 | +583.06% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $10.49 | +23.93% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.48 | - | 8 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $20.95 | +19.33% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.55 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $27.07 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $32.68 | -78.58% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $30.07 | -30.16% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.47 | - | 2 | Feb 15, 2017 |
Travere Therapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $30
Current: $15.63
Upside: +91.94%
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $12
Current: $0.61
Upside: +1,870.44%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $75
Current: $4.20
Upside: +1,685.71%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $12.30
Upside: +387.80%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $3.72
Upside: +101.61%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $3.31
Upside: +292.75%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $3.65
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.40
Upside: +1,407.54%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $7.41
Upside: +844.67%
DURECT
Mar 27, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.84
Upside: -
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $18.25
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $12
Current: $0.31
Upside: +3,808.79%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.58
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $8.25
Upside: +287.88%
Mar 10, 2025
Maintains: Buy
Price Target: $24 → $35
Current: $62.90
Upside: -44.36%
Mar 3, 2025
Maintains: Buy
Price Target: $72 → $75
Current: $48.37
Upside: +55.05%
Feb 28, 2025
Reiterates: Buy
Price Target: $29 → $21
Current: $9.16
Upside: +129.26%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $52.02
Upside: +38.41%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $302.17
Upside: +34.03%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $4.33
Upside: +27.02%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $28.44
Upside: +234.04%
Feb 11, 2025
Reiterates: Buy
Price Target: $18
Current: $7.11
Upside: +153.16%
Feb 7, 2025
Reiterates: Buy
Price Target: $13
Current: $3.87
Upside: +235.92%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $3.27
Upside: +52.91%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $21.28
Upside: +125.56%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $5.47
Upside: +37.11%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $0.73
Upside: +583.06%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $10.49
Upside: +23.93%
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.48
Upside: -
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $20.95
Upside: +19.33%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.55
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $27.07
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $32.68
Upside: -78.58%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $30.07
Upside: -30.16%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.47
Upside: -